阿尔波特综合征
足细胞
生物
谱系(遗传)
突变
肾小球基底膜
遗传学
肾小球肾炎
基因
基底膜
计算生物学
生物信息学
细胞生物学
肾
蛋白尿
作者
Sergio Daga,Margherita Baldassarri,Caterina Lo Rizzo,Chiara Fallerini,Valentina Imperatore,Ilaria Longo,Elisa Frullanti,Elisa Landucci,Laura Massella,Carmine Pecoraro,Guido Garosi,Francesca Ariani,Maria Antonietta Mencarelli,Francesca Mari,Alessandra Renieri,Anna Maria Pinto
摘要
Alport Syndrome (ATS) is a rare genetic disorder caused by collagen IV genes mutations, leading to glomerular basement membrane damage up to end-stage renal disease. Podocytes, the main component of the glomerular structure, are the only cells able to produce all the three collagens IV alpha chains associated with ATS and thus, they are key players in ATS pathogenesis. However, podocytes-targeted therapeutic strategies have been hampered by the difficulty of non-invasively isolating them and transcripts-based diagnostic approaches are complicated by the inaccessibility of other COL4 chains-expressing cells. We firstly isolated podocyte-lineage cells from ATS patients’ urine samples, in a non-invasive way. RT-PCR analysis revealed COL4A3, COL4A4, and COL4A5 expression. Transcripts analysis on RNA extracted from patient's urine derived podocyte-lineage cells allowed defining the pathogenic role of intronic variants, namely one mutation in COL4A3 (c.3882+5G>A), three mutations in COL4A4 (c.1623+2T>A, c.3699_3706+1del, c.2545+143T>A), and one mutation in COL4A5 (c.3454+2T>C). Therefore, our cellular model represents a novel tool, essential to unequivocally prove the effect of spliceogenic intronic variants on transcripts expressed exclusively at a glomerular level. This process is a key step for providing the patient with a definite molecular diagnosis and with a proper recurrence risk. The established system also opens up the possibility of testing personalized therapeutic approaches on disease-relevant cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI